- OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.
- While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.
- OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)
OncoSec Medical immunotherapy helps reduce tumors in mice
Oct 8 2013, 07:25 ET